Oricula Therapeutics Product History
Oricula Therapeutics' first product (ORC-13661), an oral medicine to preserve hearing during aminoglycoside therapy, has completed Phase 1 clinical testing in normal human volunteers for safety, tolerability and pharmacokinetics. The pharmacokinetics were favorable with linear dose proportionality and a long half-life (> 72 hours) facilitating daily oral dosing. ORC-13661 was well tolerated and, at doses greater than threefold above the expected clinical dose, there were no definite drug or dose related adverse events. A Phase 2 proof of efficacy clinical trial is planned.